Aardvark Therapeutics Goodwill and Intangible Assets 2023-2025 | AARD

Aardvark Therapeutics goodwill and intangible assets from 2023 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Aardvark Therapeutics Goodwill and Intangible Assets 2023-2025 | AARD

Aardvark Therapeutics goodwill and intangible assets from 2023 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$248.3B
Amgen (AMGN)$155.9B
Gilead Sciences (GILD)$142.4B
Vertex Pharmaceuticals (VRTX)$99.3B
Bristol Myers Squibb (BMY)$96.1B
GSK (GSK)$81.1B
CSL (CSLLY)$67.7B
Regeneron Pharmaceuticals (REGN)$62.3B
Alnylam Pharmaceuticals (ALNY)$59.1B
Argenex SE (ARGX)$43.3B
Insmed (INSM)$27.9B
BioNTech SE (BNTX)$25.2B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.4B
Genmab (GNMSF)$16B
Genmab (GMAB)$15.7B
Illumina (ILMN)$15.2B
Ascendis Pharma (ASND)$12B
BioMarin Pharmaceutical (BMRN)$11B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.9B
Exelixis (EXEL)$10.3B
Moderna (MRNA)$9.6B
Verona Pharma American Depositary Share (VRNA)$9.1B
Bio-Techne Corp (TECH)$8.9B
Exact Sciences (EXAS)$8.7B
Halozyme Therapeutics (HALO)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B